Analyst
Contributor's Links: Graycell Advisors Prudent Biotech

Besides being an Analyst on both the Buyside and Sellside, the author has worked in Corporate Strategy and Finance roles for technology services companies and has now been publishing risk-adjusted, return-driven, quantitative model portfolios for many years at Graycell Advisors. More ... more

ALL CONTRIBUTIONS

Biotech Bonanza: 2019 Outlook
In 2019 biotech stocks will have an uphill battle, but will still provide opportunities for attractive gains.
Read
Biotech Stocks: Tariff Safe And Building Momentum
The Nasdaq Biotechnology Index is poised to make a 52-week high and most likely an all-time high shortly thereafter.
Read
Biotech Stocks Emerge Unscathed And Ready To Go
The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.
Read
Biotechs: Still Well Placed For More Gains
The cold winds of February cut into the market as stocks found themselves going in an unaccustomed direction. Sliding like a toboggan, stocks last week experienced the sharpest correction in over 50 years, reaching the -10% mark within a week.
Read
EC 2018 Outlook – Biotech Bonanza: Biotech Stocks To Keep Shining
Biotech is not an easy sector to invest in - 95 percent of the oncology drugs that enter clinical trials fail. But that is no reason to ignore biotechs. We believe biotech stocks in 2018 will deliver double-digit returns of around 20%.
Read
Biotech: Opportunity Ahead!
December can prove to be a month of opportunity. We believe the passage of tax cuts this year can be the catalyst that jolts the biotech sector, to recover back the recent declines and even make new 52-week highs.
Read

Comments

Latest Comments
Suicide Is Painless
1 year ago

A quick market pulse!

Thanks for the key highlights of the day.

In this article: DB, GM, TSN, WFC, GOOG, SNAP
1 to 1 of 1 comments

STOCKS I FOLLOW

BXUB Barclays Bank PLC
BXUC Barclays Bank PLC
DIA SPDR Dow Jones Industrial Average
EPS WisdomTree Earnings 500 Fund
IBB iShares Nasdaq Biotechnology Index Fund
IVV iShares S&P 500 Index Fund
IWM iShares Russell 2000 Index Fund
LLSP Direxion Daily S&P 500 Bull 1.25X ETF
QQQ PowerShares QQQ Trust Series 1
RSP Rydex S&P Equal Weight ETF
RWL RevenueShares Large Cap ETF
RYARX Rydex Series Fds Inverse S&P 500 Strategy Fund
SDS ProShares UltraShort S&P500
SFLAF iPath Long Extended S&P 500 TR ETN
SH ProShares Short S&P500
SPLX UBS ETRACS M Reset 2xLvg S&P 500 TR ETN
SPUU Direxion Daily S&P 500 Bull 2X ETF
SPXE ProShares S&P 500 ex-Energy
SPXL Direxion Daily S&P500 Bull 3X ETF
SPXN ProShares S&P 500 ex-Financials
SPXS Direxion Daily S&P500 Bear 3X ETF
SPXT ProShares S&P 500 ex-Technology
SPXU ProShares Trust
SPXV ProShares S&P 500 ex-Health Care
SPY SPDR S&P 500
Load More

TWEETS

PERSONAL BLOG

Latest Posts
A Federal Reserve Jolt
Stocks have been highly volatile in October as rising concerns about the direction of interest rates have taken center stage and diminished the risk appetite of investors.
Biotech: The Gates Begin To Open
We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs
Biotech Bonanza: Biotech Stocks To Continue Higher In 2018
During 2017, the Biotechnology sector delivered a solid performance. However, the sector still remains ~15% below its all-time highs. Biotech stocks should continue performing strongly in 2018, and investors must consider a portfolio exposure.
When The Bulls Growl & The Bears Moo! Stock Market Outlook 2018
The year 2017 will be remembered as the year when the Bulls Growled and the Bears Mooed.
Biotech Bonanza: Breaking New Ground!
Biotechnology has started off the year on a strong note, and finally breached a level that presented stiff resistance in the past.

Work Experience

Education

Publications

Prudent Biotech
Tarun Chandra, CFA
Graycell Advisors
Tarun Chandra, CFA